Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
n2k- we are in an enviable position in that the generic (us) might very easily become the industry standard. It is already better than Embeda and our manufacturing process may set the standard for many other drugs. The smaller the bead the better.
n2k-Hope you are right.
Thanks Couch and Thanks lasers.
Our revenues were 8.5% ahead of last quarter and even better from the same quarter last year. What is wrong with those results. I have lost count of the number of quarters in a row we have increased our revenue. On any other exchange the SP would have gone up.
n2k-Hilarious! Great job! I am sure a lot of DD went into each of those so-called facts. Your right their should be a BS index or chart.
Everybody keep hitting the ask. MMs will use a lot of naked shorts today in an effort to bring it down. But they have to cover the buys today. It will in the end be a bad day for MMs because no matter how hard they try to bring it down before the CC it will be green at the end of the day.
By having Embeda on the market first and seeing the pricing structure will also help ELTP come up with a better evaluation of its worth. I would not underestimate the ability of ELTP to capture a very large part of the market
toofun-I could not agree more. The problem is they hold life and death of many good companies in their schizophrenic hands.
The FDA is in a face saving mode. They have egg on their face from PFE and Embeda and really did themselves in on Zohydro for which even Congress got on their case. The FDA will time this so Embeda will be first to market. PFE has invested millions and millions of dollars beyond what ELTP has spent or ever will spend to get El200 to market. PFE shareholders would be filing lawsuits if they knew what happened to Embeda just to get it to market and how much they have spent. The FDA it appears is giving free passes for Embeda and Zohydro. Then ELTP will be up next. Our product is better, can be formulated in many ways, and can grossly undersell PFE . I am glad Embeda will go on the market first so we can see what the price structure is going to be. What ever it is Embeda will not last long on the market or PFE is going to have to lose a lot more money than they already have just to keep it on the market which they probably will have to do unless the CEO wants to lose his job. The only good thing PFE can say about Embeda is that they can pass the hot potato to Purdue and let them deal with all the lawsuits.
Having Embeda on the market is a big help for ELTP. Since Embeda will be on the market, then any other product thereafter of similiar focus will require less scrutiny from the FDA since ELTP will essentially be copycats. Also the lienency showed toward Zohydro by not requiring additional studies also helps. It won't matter if Emeda is first to market because BE studies already show ELTP to be a better product. Physicians and patients will vote and ELTP will easily come out on top. The different combinations associated with an initial winning product life El-200 will be even more favorable in the physicians eyes. I am sure it was quite expensive after all these years to produce Embeda. I will also be interested in the price of Embeda and I bet ELTP will easily be able to produce El-200 much cheaper. So a better product, cheaper, and more flexible will take over the market.
Just think -it won't be much longer and they will not have to try so hard to find something to post anymore.
Here we go again! Lots of red volume lines but increasing sp. MMs working hard trying to hold this down. As usual
Yj4life-I agree. Once you know the OTC game you just buy,hold, and accumulate.
Again, I can't wait for the FDA to make their announcement. At that moment all the conjecture, misinformation, and misleading information will instantly be shown to be wrong and misguided. It can all be flushed down the toilet and forgotten like all the other misinformation when NH makes a PR. This happens time and time again as ELTP fulfills its goals.
Hotstocked article did not even mention actually what ELTP does. I will be so glad when the FDA gives us the go ahead. All of the nonsense will be gone instantly and it will be a brand new day and we will not have to ever look back. Buy, hold, accumulate while you can at these prices.
olameow-Even better. Buy more shares.
olameow-That is a very narrow minded financial goal. BY the time you pay taxes on your short term gain you may not even have enough money to buy back the same number of shares you sold. Hold and accumulate. You will be far better off.
With Zyhydro remember the FDA took a lot of flak for approving that med in the first place from Congress. I think the FDA had to give the go ahead so the FDA would be considered in a better light. However, this is good for us and basically reflects a change in their philosophy. I think they are getting a little frustrated waiting for Embeda as well. The flood gates may well open and this could be the first hint.
Jspila- Great observation on your part. I am just trying to keep it really simple. There are many very smart investors like yourself here. A few days on the most active list will also change things here.
In looking at the little box to the right of this screen we see little blue and red volume lines. When you see a nice long blue line immediately followed by a red line of similiar length that is a reaction by MMs with naked shorts to stop the upward momentum. Keep buying and holding and accumulating. Pretty soon MMs will just be selling naked shorts to each other. That will be the epitome of failure on their part.
The main effort by big pharma is to get Embeda to the market first. What an embaressment for big pharma. This is due this month if it is going to happen. In the end this is all big pharma can do. BE studies show ELTP has a better product. It will not take long for the real market makers-the doctors and the patients -to realize this. Big pharma has had problems for years just bringing this single one product to market. ELTP can bring many of those products and choices to market very quickly. The numbers will be overwhelmingly in favor of ELTP.
Tangerine-As usual great point. It shows in one aspect how desperate the FDA is. I am sure Camargo has noted this and will point this out to the FDA if their demands go beyond reason.
Snup- That catch that put them in scoring position adds a new dimension to "bobble-head". Unforyunately, we could call that interception the "immaculate interception."
ZGNX news will help ELTP today. First it continues to bring attention to the problem putting more political pressure on the FDA. Any DD at all will reveal that it won't work. A little more DD will reveal how ELTP will be successful.
It is so very obvoius that there has been a concerted and coordinated effort to control the SP and PRs about ELTP. Beyond question this is an effort by big pharma. There is no doubt. In the end the political pressure on the FDA will win out. The absolute single best thing as shareholders we can do beyond question is to buy these cheap shares, hold, and accumulate. Just follow what the insiders are doing. It does not get any easier than this. Going short at this time is absolutely crazy. Shorts must cover now. Flippers are going to have a lot fewer opportunities for flipping unless you have a super fast computer. We are looking at a long climb upward shortly.
JL-If the trade is unknown then it can be classfied as a buy or sell to the advantage of the MMs. In addition, their are a whole host of nonretailer individual dark market MMs and trades that go unknown. In fact it is estimated that 30% of trades go unlisted or are not known by the SEC on the OTC.
Aegidius- My best guess is that big pharma is behind this and MMs get paid to depress this stock. It has gotten so black and white. Like Couch says-look at the facts. Look at the SP. Look at the quarter after quarter increase in profits. Does not make sense and something else is going on.
Aegidius- Thank you for your following L2 so closely. Unfortunately, as you well know, this happens all the time and I do not need to tell you that. It is only going to get worse. MMs can pretty much do what ever they want. I believe in charts but really only for NYSE where things are better regulated. Snup mentioned his disgust today as well. The more desperate MMs get the dirtier it gets. Recording buys as sells and sells as buys hardly makes for accurate charts. Just buy,hold accumulate like the insiders are doing. We just need one more PR.
Against the volume in the millions yesterday, 50,000 short is not bad and better than usual. Its a problem- were those 50,000 shares retailers or was that 50,000 naked shorts by MMs. MMs routinely use 1000 share lots to drive the price down by continually undercutting the bid and SP. Gradually, the MMS will finally lose their death grip on this stock. Their goal is to keep this stock in their control on the OTC -they like making money off this stock. They would hate to see this go to the NasD.
I think NH is just waiting on the FDA. Once we get the go ahead then I think NH is going to hit the PR hard.
My favorite part of the article is the mention of market makers "squashing" this stock. How true!!!
no2koolaid and rdragon- Nice rationale posts.
Hike- Simply great DD. Another competitor derailed. MMs fighting a losing battle today.
MMs very heavy handed today and really trying hard to push the SP down. The harder they try the more I buy. They are very nervous about something. Their fun and games are about over.
Sitten bull- I agree. MMs have control of as many naked shares as they want.
Steve- Thanks for the Level 2 update. MMs just trying to set the tone for the week and failing as usual. Shareholders here too smart for that old and worn out ploy. JT single handedly financially saved this company and now NH is going to carry ELTP across the finish line very shortly.
Very funny to see red volume lines with a rising share price.
Aegidius-It looks good on paper but everyone knows that MMs are greedy and want to make more than just their comission for creating markets. Where have you been? It is standard for MMs to start the day in the red for ELTP. Something is up and something big is coming soon. Just an MM last ditch effort to grab more shares.
Senderos- Yes, I do. ELTP approach is cheaper, easier, further along in research, closer to production, can work with any medication, will be first to market. What is there not to like. We have been flying under the radar so with a great PR we can get an idea how ELTP will take off as well when NH decides to make an announcement.
jtf3- Oh yes the market cares about generic drugs. Ins. co. and big pharma know this. The generic market is a lot bigger and very important especially to ins. co. and patients. Cheaper drugs, happy ins. co., happy patients.